Current Status of Human Papillomavirus–Targeted Therapies Development in Head and Neck Cancer Twelve RCTs were included in our meta-analysis, with a total of 3,565 patients. We observed that ...
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
SAN FRANCISCO and SUZHOU,China, April 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody. Data from the MARIPOSA study (NCT04487080) support this newest approval, and ...
BERLIN -- An antibody-drug conjugate targeting Trop2 significantly improved survival outcomes compared with platinum-based chemotherapy in pretreated patients with EGFR-mutated non-small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results